GlassScriptPhysician profile
Neha Tyagi
NPI 1518372986
$5,753.10
in general payments reported to CMS, 2019-2025
35 companies · $928 in 2025
The $928 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.43 · 2021: $288 · 2022: $679 · 2023: $1,984 · 2024: $1,858 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,769.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,655.88 | 2023-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $556.40 | 2021-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.04 | 2021-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $294.09 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $288.01 | 2023-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $262.40 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $254.05 | 2023-2025 | |
| Daiichi Sankyo INC. | $252.11 | 2023-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $201.57 | 2021-2024 | |
| Lilly USA, LLC | $189.63 | 2023-2024 | Jardiance, Emgality, Mounjaro |
| Alk-Abello, INC | $184.94 | 2023-2025 | Odactra, Grastek, Ragwitek |
| Merck Sharp & Dohme LLC | $183.73 | 2020-2024 | Delstrigo, Pifeltro, Gardasil 9 |
| Exact Sciences Corporation | $176.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $138.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $106.22 | 2023-2024 | Spravato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $87.35 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.39 | 2022 | |
| Astellas Pharma US INC | $59.06 | 2023-2024 | Veozah |
| Dexcom, INC. | $57.14 | 2024-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $56.54 | 2024-2025 | Aptima |
| Indivior INC. | $51.00 | 2023-2024 | Sublocade |
| Janssen Biotech, INC. | $36.70 | 2024 | Tremfya |
| Kyowa Kirin, INC. | $31.99 | 2023 | Crysvita |
| Viiv Healthcare Company | $30.84 | 2024 | Apretude |
| Regeneron Healthcare Solutions, INC. | $26.26 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.53 | 2022 | |
| Theratechnologies INC. | $21.90 | 2023 | Trogarzo, Egrifta |
| Qiagen, LLC | $20.39 | 2024 | |
| Sanofi Pasteur INC. | $19.23 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.37 | 2025 | Nuzyra |
| Optinose US, INC. | $16.21 | 2025 | |
| Scilex Pharmaceuticals INC. | $15.68 | 2022 | |
| Cranial Technologies, INC | $14.70 | 2024 | Doc Band |
| Redhill Biopharma INC. | $14.37 | 2022 | |
| Insmed, INC. | $13.52 | 2023 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Tyagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.